Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2–β‐catenin/TCF4‐survivin pathway in ErbB2‐overexpressed breast cancer cells
- 19 April 2010
- journal article
- Published by Wiley in Cancer Science
- Vol. 101 (5) , 1156-1162
Abstract
Overexpression of ErbB2 is associated with poor prognosis in breast cancer. Targeting of ErbB2 is a very common therapeutic strategy in ErbB2‐overexpressed breast cancer. Herceptin is the first approved and most widely used agent for ErbB2‐targeting therapy in breast cancer. Even though the clinical application has been performed for more than 10 years, the exact mechanism underlying how Herceptin exhibits its effects has not been fully elucidated. In this study, we found that Herceptin could inhibit the expression of survivin in ErbB2‐overexpressed cell lines. Overexpression of survivin could abrogate the inhibition of cell growth induced by Herceptin. Herceptin could reduce survivin expression at the transcriptional level. The β‐catenin/T‐cell factor (TCF) pathway played a very crucial role in this cascade. We found that Herceptin could reduce tyrosine phosphorylation levels of ErbB2 and β‐catenin. Herceptin treatment induced degradation of β‐catenin protein, resulting in reduced binding affinity of β‐catenin/TCF4 to the promoter region of survivin. When we cross‐mutated the TCF4 binding sites in the promoter region of survivin, the reduction of survivin promoter activity almost diminished. Taken together, we showed that Herceptin could inhibit survivin expression through the ErbB2–β‐catenin/TCF4‐survivin pathway in ErbB2‐overexpressed breast cancer cells. This indicates that there may be a new cascade axis from ErbB2 to survivin.(Cancer Sci 2010; 101: 1156–1162)Keywords
This publication has 30 references indexed in Scilit:
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineThe Oncologist, 2009
- Her2-positive breast cancer: Herceptin and beyondEuropean Journal of Cancer, 2008
- Cancer cells survive with survivinCancer Science, 2008
- Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathwaysBMC Cancer, 2008
- Survivin, cancer networks and pathway-directed drug discoveryNature Reviews Cancer, 2008
- Integrating signals from RTKs to ERK/MAPKOncogene, 2007
- Survivin Expression Is Regulated by Coexpression of Human Epidermal Growth Factor Receptor 2 and Epidermal Growth Factor Receptor via Phosphatidylinositol 3-Kinase/AKT Signaling Pathway in Breast Cancer CellsCancer Research, 2005
- Perturbations of the AKT signaling pathway in human cancerOncogene, 2005
- Survivin, versatile modulation of cell division and apoptosis in cancerOncogene, 2003
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987